Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel